Capital Research Global Investors’s Quince Therapeutics QNCX Stock Holding History

Capital Research Global Investors’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,579	Closed	-$212M	–	458
2021 Q3	$212M	Hold	11,579	–	–	0.05%	243
2021 Q2	$123M	Sell	11,579 -1,450	-11%	-$12.2M	0.03%	286
2021 Q1	$93.9M	Hold	13,029	–	–	0.02%	319
2020 Q4	$72.4M	Hold	13,029	–	–	0.02%	325
2020 Q3	$130M	Hold	13,029	–	–	0.04%	250
2020 Q2	$121M	Buy	13,029 +321	+3%	+$2.94M	0.04%	252
2020 Q1	$116M	Buy	12,708 +493	+4%	+$4.87M	0.05%	222
2019 Q4	$137M	Hold	12,215	–	–	0.04%	238
2019 Q3	$60.1M	Buy	+12,215	New	+$75.2M	0.02%	305

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital Research Global Investors's QNCX Position: Q4 2021 in Review

Capital Research Global Investors sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 11,579 shares — an estimated $212M sold.

Capital Research Global Investors first reported a position in QNCX in Q3 2019 and held it in 9 quarters. The position peaked at $212M in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Capital Research Global Investors reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Capital Research Global Investors sold 11,579 Quince Therapeutics shares in Q4 2021, an estimated $212M.
Capital Research Global Investors first reported a position in Quince Therapeutics in Q3 2019 and held it in 9 quarters.
Capital Research Global Investors's Quince Therapeutics position peaked at $212M in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Capital Research Global Investors's 13F filing for Q4 2021, filed 14 Feb 2022.